Skip to main content


Fig. 3 | BMC Research Notes

Fig. 3

From: Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

Fig. 3

Tumor growth kinetics of murine orthotopic a RT112luc and b RT112rGEMCI20luc xenografts. Dasatinib was given per oral gavage at a dose of 20 mg/kg body weight (BW) twice daily. Control animals were vehicle-treated in the same way. 10 × 108 photons/s correlate to 10 mm3 tumor volume (21). c Representative photographs of treated and untreated RT112luc and RT112rGEMCI20luc xenografts with fluorescent bladder tumors

Back to article page